MannKind Corporation (MNKD) Stock

MannKind Corporation (MNKD) is a Healthcare stock trading at $3.94 (as of 2026-06-18), with a market capitalization of $1.16B and a trailing P/E of -53.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing inhaled therapies for endocrine and orphan lung conditions in the United States. It markets Afrezza for glycemic control in adults with diabetes and promotes Thyquidity for hypothyroidism, serving endocrinologists and other healthcare providers, and it also has collaborations related to therapies such as aviptadil.

Valuation — source: SEC EDGAR (first-party)
Price	$3.94
Market Cap	$1.16B
P/E Ratio	-53.9
EV / EBITDA	45.6
Price / Book	-19.68
Price / Sales	3.23
DCF Value (model)	$-0.15
DCF Upside vs Price	-103.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$348.97M
Net Margin	1.7%
Return on Equity	40.4%
Debt / Equity	-5.38
Current Ratio	1.87
Revenue Growth (YoY)	22.2%
EPS Growth (YoY)	-80.0%
FCF Growth (YoY)	-58.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.00 (distress)
Piotroski F-Score	3/9 (weak)

Valuation vs Sector & Industry
Stock P/E	-53.9
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-357.0%
vs Industry	-412.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($101.38M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael E. Castagna
Employees	403
Country	US
IPO Date	2004-07-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.